About CatalystPharma
CatalystPharma is a company based in Coral Gables (United States) founded in 2002 by Hubert E Huckel and Patrick James Mcenany was acquired by Angelini Pharma in May 2026. The company has 181 employees as of December 31, 2024. CatalystPharma offers products and services including Approved Products and Clinical Pipeline. CatalystPharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Biogen, among others.
- Headquarter Coral Gables, United States
- Employees 181 as on 31 Dec, 2024
- Founders Hubert E Huckel, Patrick James Mcenany
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Catalyst Pharmaceuticals, Inc.
-
Annual Revenue
$491.73 M (USD)23.49as on Dec 31, 2024
-
Net Profit
$163.89 M (USD)129.5as on Dec 31, 2024
-
EBITDA
$233.18 M (USD)94.39as on Dec 31, 2024
-
Latest Funding Round
$37.38 M (USD), Post-IPO
Feb 04, 2015
- Investors
-
Employee Count
181
as on Dec 31, 2024
-
Acquired by
Angelini Pharma
(May 08, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CatalystPharma
CatalystPharma is a publicly listed company on the NASDAQ with ticker symbol CPRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CatalystPharma
CatalystPharma offers a comprehensive portfolio of products and services, including Approved Products and Clinical Pipeline.
Medications for rare diseases like LEMS and DMD
Development of treatments for neurological conditions
People of CatalystPharma
Unlock access to complete
Unlock access to complete
Funding Insights of CatalystPharma
Investors in CatalystPharma
CatalystPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Angelini Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer and developer of active ingredients, branded drugs, medical products and dietary supplements
|
Locked | Locked | Locked |
Investor details for CatalystPharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CatalystPharma
Investment portfolio details for CatalystPharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CatalystPharma
Detailed financials for CatalystPharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Catalystpharma Comparisons
Peer comparison for CatalystPharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CatalystPharma
CatalystPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Biogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
Detailed competitors of CatalystPharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Catalystpharma
Complete news archive for CatalystPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CatalystPharma
CatalystPharma was founded in 2002 and raised its 1st funding round 11 years after it was founded.
CatalystPharma is headquartered in Coral Gables, United States. It is registered at Coral Gables, Florida, United States.
Patrick James Mcenany is the current CEO of CatalystPharma. They have also founded this company.
As of Dec 31, 2024, the latest employee count at CatalystPharma is 181.
Annual revenue of CatalystPharma is $491.73M as on Dec 31, 2024.
CatalystPharma was founded in 2002 and is headquartered in Coral Gables, United States. Operations center on the development and commercialization of prescription drugs that target rare debilitating conditions, including Lambert-Eaton Myasthenic Syndrome, infantile spasms, and Tourettes disorder. Focus is placed on the pharmaceutical sector, with emphasis on neuromuscular and neurological diseases affecting limited patient populations.
CatalystPharma's top competitors include Moderna, Jazz Pharmaceuticals and Spark Therapeutics.
CatalystPharma offers Approved Products and Clinical Pipeline.
Yes, CatalystPharma is publicly traded on NASDAQ under the ticker symbol CPRX.
CatalystPharma has 1 investor. Key investors include Angelini Pharma.
The ticker symbol of CatalystPharma is CPRX on NASDAQ.